Myria Biosciences AG

📍 Basel, Switzerland🗓 Founded 2022👥 7 employees💰 Last funded Jan 2024
Biotechnology Research🌐 myria.bio
Website LinkedIn
Myria Biosciences aims to reshape drug discovery with synthetic intelligence to engineer natural-product inspired chemical compounds for pharma and biotech challenges. The companys GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform combines synthetic biology and artificial intelligence into a synthetic intelligence approach that allows therapeutic compound design and biological production far beyond what natures evolution has provided. Myria is unlocking new chemical space and generating optimized molecular candidates with unprecedented speed and precision for unmet medical needs.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Myria Biosciences AG?
Myria Biosciences AG has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Myria Biosciences AG last raise funding?
The most recent investment in Myria Biosciences AG recorded on gritt.io was in January 2024.
When was Myria Biosciences AG founded?
Myria Biosciences AG was founded in 2022.
What industry is Myria Biosciences AG in?
Myria Biosciences AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Myria Biosciences AG based?
Myria Biosciences AG is headquartered in Basel, Switzerland.